Navidea Biopharma (NAVB) to Sublicense NAV4694 Worldwide Development Rights

April 16, 2018 7:08 AM

Navidea Biopharmaceuticals (NYSE: NAVB) (“Navidea” or “the Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found